Eisai R&d Management Co., Ltd.

Epizyme, Inc.

Arani Chanda

Kristen Sanders

Kevin Wayne Kuntz

Steven Mathieu

Hyeong Wook Choi

Kuan-Chun Huang

Francis Gerard Fang

John JianShi Wang

Sudeep Prajapati

George Moniz

Kenshi Yoshida

Frances Fang

Guo Zhu Zheng

Ming-Hong Hao

Atsushi Endo

Dominic J Reynolds

Yoshihiko Kotake

Hyeong-wook Choi

Gregg F Keaney

Peter G Smith

Kazunobu Kira

Parcharee Tivitmahaisoon

Takashi Satoh

Frank Fang

Norio Murai

Silvia Buonamici

Baudouin Gerard

Lihua Yu

Anand Selvaraj

Xiang Liu

Ermira Pazolli

Satoshi Nagao

Eunice Sun Park

Masayuki Miyano

Kian Huat Lim

Kenzo Arai

Nicholas C Gearhart

Regina Mikie Kanada Sonobe

Michael P Thomas

Betty Chan

Hyeong-Wook Choi

Regina Mikie Kanada Sonabe

Dominic Reynolds

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

Salt form of a human histone methyltransferase EZH2 inhibitor

A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.

Crystalline FGFR4 inhibitor compound and uses thereof

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1&#x2032;-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful. 

Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof

Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1&#x2032;-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.

Hydrochloride salt form for EZH2 inhibition

A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.

Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1&#x2032;-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1&#x2032;-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

Growing community of inventors

Malden, MA, United States of America

Arani Chanda